CAC
TARA icon

Cowen and Company’s Protara Therapeutics TARA Stock Holding History

Cowen and Company’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-124,171
Closed -$2.09M – 514
2020
Q3 		$2.09M Buy
+124,171
New +$2.88M 0.34% 50

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cowen and Company's TARA Position: Q4 2020 in Review

Cowen and Company sold out of Protara Therapeutics (TARA) in Q4 2020, closing a stake of 124,171 shares — an estimated $2.09M sold.

Cowen and Company first reported a position in TARA in Q3 2020 and held it in 1 quarter. The position peaked at $2.09M in Q3 2020. 49 funds tracked by Wall St. Rank hold TARA as of Q4 2020.

  • Cowen and Company reported no remaining Protara Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Cowen and Company sold 124,171 Protara Therapeutics shares in Q4 2020, an estimated $2.09M.
  • Cowen and Company first reported a position in Protara Therapeutics in Q3 2020 and held it in 1 quarter.
  • Cowen and Company's Protara Therapeutics position peaked at $2.09M in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.